WisdomTree Investments has launched the WisdomTree BioRevolution Fund (WDNA) on the CBOE. WDNA seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (WTDNA), and has an expense ratio of 0.45 per cent.
“The biology revolution is creating a historic investment opportunity equivalent to the industrial and internet revolutions,” says Jeremy Schwartz, Global Head of Research at WisdomTree. “The WisdomTree BioRevolution Fund offers diversified exposure to a basket of companies that we believe is uniquely positioned to seize the opportunity at the intersection of biology and technology. This launch represents the latest in our ongoing commitment to offering investors innovative investment opportunities.”
WisdomTree leveraged data from Dr Jamie Metzl, one of the world’s leading technology futurists and Special Strategist for WisdomTree, in its construction of the WisdomTree BioRevolution Index, which identifies the key sectors and industries that are expected to be most significantly transformed by advances in biological science and technology.
“The genetics and biotechnology revolutions won’t just change our healthcare systems, allowing us to live healthier and longer lives,” explains Dr Jamie Metzl, author of Hacking Darwin: Genetic Engineering and the Future of Humanity. “They will also fundamentally transform our world far beyond healthcare. The same technologies driving healthcare innovation will have a seismic impact on industries including agriculture, materials, energy, and information processing, revolutionising the ways we treat disease, grow food,produce materials, and process data. If the nineteenth was the century of chemistry and the twentieth of physics, the twenty-first will be the century of biology. I am delighted to be collaborating with the amazing team at WisdomTree in uncovering the massive opportunities of this historic megatrend.”
